ReviewDrug design, development and therapy2021
The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date.
Review in Drug design, development and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Efficacy and tolerability of native (undenatured) type II collagen supplementation for joint health in healthy volunteers: a randomized double-blind placebo-controlled study.Nutrition journal · 2026Trial
- Efficacy and safety of Latilactobacillus sakei LB-P12 in patients with knee osteoarthritis: an exploratory randomized, double-blind, placebo-controlled clinical trial.Scientific reports · 2025Trial
- An ultrasound-responsive hydrogel with piezoelectric-enhanced bioelectric-vesicular coupling alleviates mitochondrial dysfunction and inflammation for osteoarthritis therapy.Bioactive materials · 2027Article
- Molecular hydrogen and osteoarthritis: multi-target mechanisms and therapeutic effectiveness.Medical gas research · 2027Review
- Immune dysregulation in osteoarthritis: Mechanisms, biomarkers, and therapeutic opportunities.Journal of translational autoimmunity · 2026Review
- Fhl2 promotes chondrocyte ferroptosis in osteoarthritis by impairing mitophagic flux through microtubule disorganization.Cell death and differentiation · 2026Article
- Predicting Knee osteoarthritis progression using explainable machine learning and clinical imaging data.Osteoarthritis and cartilage open · 2026Article
- Spermidine, a chondrocyte apoptotic metabolite, delays osteoarthritis by regulating macrophage M2c polarization.Journal of nanobiotechnology · 2026Article
- Large-scale molecular endotype discovery in synovial fluid reveals osteoarthritis as a single biological continuum.Nature communications · 2026Article
- Aptamer-Functionalized Nanocarriers for Bone and Joint Diseases: Engineering Design Rules and Translational Roadmap.Small science · 2026Article
- Evaluating the utility of prognostic enrichment in clinical trials: Applications to clinical trial design in osteoarthritis.Osteoarthritis and cartilage · 2026Article
- Long term safety and efficacy of a functionalized nanogel with endothelin-1 and bradykinin receptor antagonist peptides for treatment of osteoarthritis of the metacarpophalangeal and distal interphalangeal joints in horses: a descriptive clinical pilot study.BMC veterinary research · 2026Article
- Integration of gold standard arthroscopy, MRI and synovial histopathology outcomes for enhancing early knee osteoarthritis diagnosis.Aging clinical and experimental research · 2026Article
- The role of radiography and MRI as screening tools and outcome measures in clinical trials of knee osteoarthritis: a perspective on the current status and outlook.Therapeutic advances in musculoskeletal disease · 2026Review
- Licorice-derived prenylated chalcones alleviate knee osteoarthritis via multi-target modulation of PI3K-Akt, MAPK and HIF-1α signaling: an integrative UPLC-Q-TOF-MS/MS, network pharmacology and molecular dynamics study.Frontiers in bioinformatics · 2026Article
- STOML2 Alleviates Osteoarthritis by Regulating Mitochondrial Energy Metabolism and Oxidative Stress.Genetics research · 2026Article
- Microgravity-induced transcriptional reprogramming in embryonic chicken limb bud-derived chondrogenic cultures.Frontiers in cell and developmental biology · 2026Article
- Effects of pentosan polysulfate sodium on joint structure and function out to six months in naturally-occurring canine osteoarthritis.PloS one · 2026Article
- Research progress on the role of CD14 in osteoarthritis.Frontiers in immunology · 2026Review
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a complex heterogeneous articular disease with multiple joint tissue involvement of varying severity and no regulatory-agency-approved disease-modifying drugs (DMOADs). In this review, we discuss the reasons necessitating the development of DMOADs for OA management, the classifications of clinical phenotypes or molecular/mechanistic endotypes from the viewpoint of targeted drug discovery, and then summarize the efficacy and safety profile of a range of targeted drugs in Phase 2 and 3 clinical trials directed to cartilage-driven, bone-driven, and inflammation-driven endotypes. Finally, we briefly put forward the reasons for failures in OA clinical trials and possible steps to overcome these barriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.